3 citations
,
July 2023 in “International journal of molecular sciences” This review discusses the association between emotional stress-related neuropeptides and the pathogenesis of alopecia areata, reporting no new experimental findings.
April 2025 in “Apollo Medicine” In this observational study, researchers found a significant association between alopecia areata and thyroid abnormalities, though not with diabetes mellitus, highlighting the importance of evaluating and managing these conditions holistically in affected patients.
June 2026 in “American Journal of Dermatopathology” This review describes various T-cell-mediated alopecias characterized by distinct lymphocytic patterns and explores their pathophysiology. It highlights the role of CD8+ and regulatory T cells, the JAK/STAT pathway, and stem cell niches, contributing to understanding and potentially addressing these hair loss conditions.
20 citations
,
December 2020 in “Frontiers in Immunology” This study found that certain T cell-associated genes were upregulated in dogs with Vogt-Koyanagi-Harada syndrome and vitiligo, suggesting a shared immunopathogenesis with humans.
January 2023 in “Indian Dermatology Online Journal” This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.
November 2017 in “British Journal of Dermatology” Genes controlling hair growth and immune response are disrupted in male pattern baldness.
70 citations
,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.
June 2026 in “Frontiers in Immunology” This review highlights the potential for JAK inhibitors to effectively treat inflammatory and autoimmune skin diseases by targeting the JAK-STAT signaling pathway, advocating for an integrated approach to enhance targeted therapy.
This study outlines treatment strategies for autoimmune alopecia areata, detailing that while mild cases may resolve on their own, severe cases often require intervention, with new JAK inhibitors like baricitinib and ritlecitinib emerging as promising treatments for those not responding to traditional therapies.
124 citations
,
October 2019 in “Frontiers in Immunology” This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.
14 citations
,
March 2017 in “Genes and immunity” Certain microRNAs may help treat alopecia areata by targeting immune pathways.
May 2018 in “Journal of dermatology and dermatitis” This review discusses the role of PRP in treating androgenetic alopecia and alopecia areata, but reports no new clinical results and emphasizes the potential of growth factor signaling as a future therapy.
1 citations
,
February 2021 in “Farmacja Polska” This article reviews the role of the JAK-STAT pathway in inflammatory skin diseases and considers the therapeutic benefits of JAK inhibitors, presenting them as promising treatments but reports no new experimental results.
May 2024 in “Archives of dermatological research” This study found that Enz_MoriL, a compound derived from Morus alba L., promotes hair follicle cell proliferation by affecting the Wnt/β-catenin pathway and can counteract an alopecia areata-like condition by suppressing the JAK-STAT signaling in human hair follicle dermal papilla cells.
April 2021 in “International journal of advanced research” This study found that Covid-19 may trigger autoimmune pathways leading to alopecia areata and telogen effluvium, highlighting a connection that warrants further investigation.
April 2021 in “Zenodo (CERN European Organization for Nuclear Research)” In this study, Covid-19 was found to trigger alopecia areata and telogen effluvium by activating different autoimmune pathways, indicating a connection between these hair loss conditions and the virus.
290 citations
,
December 2017 in “Journal of The American Academy of Dermatology” This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.
155 citations
,
December 2002 in “Journal of Investigative Dermatology” This study found that thyroid-stimulating hormone receptors are functionally expressed in various skin cells, implying potential physiological and pathological roles in skin, especially in conditions like autoimmune diseases.
56 citations
,
October 2016 in “Journal of dermatological science” This review explores multidisciplinary advances in understanding alopecia areata, including epidemiology, pathogenesis, and innovative treatments, but reports no new research results.
43 citations
,
June 2018 in “Clinics in dermatology” This review discusses the variety of skin disorders associated with atopic dermatitis, exploring their complex relationships and shared genetic and environmental factors, but reports no new clinical results.
5 citations
,
October 2025 in “Expert Review of Clinical Immunology” This article reviews current and emerging treatments for alopecia areata, emphasizing the need for biomarker-driven patient stratification to optimize therapeutic strategies and reduce potential side effects; it reports no new clinical findings.
This chapter reviews recent developments in vitiligo research, highlighting the role of melanocyte stem cell differentiation and oxidative stress in its management, but reports no new clinical results.
March 2026 in “Tạp chí Da liễu học Việt Nam” In this review, researchers conclude that immune imbalance between regulatory and cytotoxic T cells, along with activation of IFN-γ–MHC and IL-15–NK pathways, disrupts hair follicle immune privilege, suggesting pivotal mechanisms in alopecia areata development and potential targets for immunotherapeutic interventions.
November 2025 in “Frontiers in Immunology” This review integrates studies on mouse models and human clinical observations to highlight the role of immune cells in skin development and how their dysregulation leads to skin disorders, suggesting potential therapeutic pathways for skin regeneration.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” This case report highlights that Baricitinib led to significant hair regrowth and resolution of atopic dermatitis symptoms in a 22-year-old female with coexisting autoimmune conditions.
October 2024 in “International journal of medicine and psychology.” In this study, researchers explored the immunological mechanisms involved in alopecia areata and suggested that targeting immune responses, particularly using JAK inhibitors and other immunomodulatory drugs, could help achieve stable remission and improve patients' quality of life.
October 2024 in “The American Journal of Gastroenterology” This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.
10 citations
,
August 2019 in “European Journal of Dermatology” This abstract provides no new clinical results; it discusses the role of surgery and interventional radiotherapy in treating cutaneous squamous cell carcinoma.
July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
January 2011 in “Repository KITopen (Karlsruhe Institute of Technology)” This study suggests that contact sensitizers may treat alopecia areata by expanding suppressor cells and interfering with antigen presentation to lymphocytes.